S'abonner

Phosphatidylethanol (Peth) in Dried Blood Spots: Development, validation and comparison between LC-MS/MS and QTOF methods - 15/08/22

Doi : 10.1016/j.toxac.2022.06.065 
Christina Ververi 1, , Marta Massano 1, Enrico Gerace 2, Eugenio Alladio 3, Marco Vincenti 3, Alberto Salomone 3
1 Chemistry, University of Turin, Turin, Italy 
2 Centro regionale antidoping, Orbassano, Italy 
3 Chemistry, University of turin, centro regionale antidoping, Turin, Orbassano, Italy 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Aim

Validation of Phosphatidylethanol (Peth) in Dried Blood Spot (DBS) technique as a biomarker for routine diagnosis of alcohol abuse.

Introduction

According to recent studies, alcohol abuse in the population is increasing, forcing clinical and forensic toxicology laboratories to work towards effective and quick-turnout results techniques. In this context, detecting Peth, a relatively new biomarker, with the Dried Blood Spots, a micro sampling technique based on a capillary blood drop collection on a filter paper, may be the procedure of choice. Peth is a group of phospholipids serving as direct, non-oxidative alcohol biomarkers, only formed within the human body when ethanol is present. Peth concentrations provide information about a person's drinking behavior and offer a longer alcohol detection window up to 1 month. It is applicable as a complement to Ethyl glucuronide (EtG) for the better distinguishing of alcohol abusers from social drinkers.

Method

Blank whole blood drops were spiked with Peth 16:0–18:1 at six concentration levels (20, 50, 100, 200, 300, 500ng/mL) in three working sessions along five days. 30μl of blood was deposited on the DBS card and left for 3h drying at room temperature. After liquid extraction with 1mL of hexane, the supernatant was transferred into a fresh tube prior to evaporating the solvent under a nitrogen flow at room temperature. The dry residue was reconstituted in 30μl of acetonitrile and then injected. The detection of Peth was achieved with both UHPLC-QTOF-HRMS and UHPLC-MS/MS.

Results

Statistical evaluation of several validation parameters was executed, and the values obtained from the two different acquisition methods were found to be similar. Intra- and inter-day precision and accuracy were found to be lower than ±20% in both methods. The LOD and LOQ calculated with the Hubaux-Vos approach were 19.8 and 39.7ng/ml for, respectively, the QTOF and the MS/MS acquisition. Recovery, matrix effect and stability parameters from the analysis of Peth and its respective internal standards Peth-D5 were evaluated. A moderate ion suppression was observed, with final values between −2.7 and −14% (tested at the 20ng/ml level of concentration) and the method showed an extraction efficiency higher than 30% (tested at the 500ng/mL level of concentration). The two methods were also tested with real samples within an ongoing project and their performance was compared.

The extraction method and the DBS technique proved effective for the detection of Peth, with excellent results ensuring rapid assessment of the biomarker levels in whole blood. The precision calculated in the lower concentration range showed a slight upward deviation at 20 and 50ng/ml, which is negligible when an individual is assessed for chronic alcohol abuse (in this case, tentative cut-offs are set in the range of 200–270ng/ml). Due to the higher sensitivity obtained, the QTOF mass spectrometer proved adequate to be used for abstinence assessment in delicate clinical or forensic cases for example with newborns, organ transplant and driving relicensing.

Conclusion

Peth in DBS combined with high resolution instrumental analysis results show great potential for routine and research analysis. Thanks to this study, a larger detection window is opened thus providing the forensic toxicology laboratories an accurate, easy, sustainable, and fast technique for the challenge of alcohol abuse diagnosis.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 34 - N° 3S

P. S54 - septembre 2022 Retour au numéro
Article précédent Article précédent
  • A method for the sensitive targeted screening of synthetic cannabinoids and opioids in whole blood by LC-QTOF with simultaneous suspect screening using HighResNPS.com
  • Stephen Trobbiani, Peter Stockham, Chris Kostakis
| Article suivant Article suivant
  • Practical high resolution mass spectrometry screening approach and propositions for adequate identification criteria as well as quality assurance and validation specifics
  • Sarah Sarah Wille, Aurélien Aurélien Boland, Vincent Vincent Di Fazio, Nele Nele Samyn

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.